NORTHWEST BIOTHERAPEUTICS INC (NWBO): debt financing — Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital

NORTHWEST BIOTHERAPEUTICS INC

Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.
14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).
10% original issue discount; prepayment allowed with 10% charge.
Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.

Instrument: loan
Principal: $11,005,000
Counterparty: Streeterville Capital, LLC
Rate: 8% per annum
Maturity: 22 months
Event: incurrence

Exact text from the filing

On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2024-04-26).

Action: entry
Agreement: credit facility
Counterparty: Streeterville Capital, LLC
Value: $11,005,000
Effective: 2024-04-26

Exact text from the filing

On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.

View on SEC.gov

317 debt financings filed in the last 30 days. Browse all debt financings →

NORTHWEST BIOTHERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-056424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.